Research statistics

Liraglutide research: publications and trials

What has been published on Liraglutide: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Liraglutide works or is safe. For what it is and what the studies found, see the Liraglutide profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

4,873

Since 2001

Publications in 2026 so far

477

Through November 15, 2026

Human clinical research

35.9%

1,743 of 4,853 classified

Registered clinical trials

457

ClinicalTrials.gov

Randomized controlled trials

648

Publications reporting an RCT in people

Systematic reviews and meta-analyses

406

Preclinical studies

29.7%

1,131 animal · 212 in vitro · 100 computational

Records that only mention it

812

Not counted above

Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 20 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Liraglutide publications by year and evidence

2001, Preclinical (animal, in vitro, computational): 2 of 22002, Human clinical research: 3 of 52002, Preclinical (animal, in vitro, computational): 2 of 52003, Human clinical research: 2 of 52003, Preclinical (animal, in vitro, computational): 2 of 52003, Reviews and meta-analyses: 1 of 52004, Human clinical research: 3 of 82004, Reviews and meta-analyses: 5 of 82005, Human clinical research: 1 of 92005, Preclinical (animal, in vitro, computational): 1 of 92005, Reviews and meta-analyses: 6 of 92005, Other and not yet classified: 1 of 92006, Human clinical research: 2 of 92006, Preclinical (animal, in vitro, computational): 1 of 92006, Reviews and meta-analyses: 3 of 92006, Other and not yet classified: 3 of 92007, Human clinical research: 2 of 242007, Preclinical (animal, in vitro, computational): 4 of 242007, Reviews and meta-analyses: 17 of 242007, Other and not yet classified: 1 of 242008, Human clinical research: 7 of 252008, Preclinical (animal, in vitro, computational): 3 of 252008, Reviews and meta-analyses: 14 of 252008, Other and not yet classified: 1 of 252009, Human clinical research: 12 of 582009, Preclinical (animal, in vitro, computational): 10 of 582009, Reviews and meta-analyses: 29 of 582009, Other and not yet classified: 7 of 582010, Human clinical research: 17 of 922010, Preclinical (animal, in vitro, computational): 6 of 922010, Reviews and meta-analyses: 52 of 922010, Other and not yet classified: 17 of 922011, Human clinical research: 35 of 1192011, Preclinical (animal, in vitro, computational): 18 of 1192011, Reviews and meta-analyses: 57 of 1192011, Other and not yet classified: 9 of 1192012, Human clinical research: 39 of 1332012, Preclinical (animal, in vitro, computational): 30 of 1332012, Reviews and meta-analyses: 51 of 1332012, Other and not yet classified: 13 of 1332013, Human clinical research: 54 of 1402013, Preclinical (animal, in vitro, computational): 36 of 1402013, Reviews and meta-analyses: 38 of 1402013, Other and not yet classified: 12 of 1402014, Human clinical research: 80 of 1962014, Preclinical (animal, in vitro, computational): 64 of 1962014, Reviews and meta-analyses: 41 of 1962014, Other and not yet classified: 11 of 1962015, Human clinical research: 101 of 2602015, Preclinical (animal, in vitro, computational): 75 of 2602015, Reviews and meta-analyses: 55 of 2602015, Other and not yet classified: 29 of 2602016, Human clinical research: 100 of 2812016, Preclinical (animal, in vitro, computational): 65 of 2812016, Reviews and meta-analyses: 76 of 2812016, Other and not yet classified: 40 of 2812017, Human clinical research: 104 of 2922017, Preclinical (animal, in vitro, computational): 76 of 2922017, Reviews and meta-analyses: 72 of 2922017, Other and not yet classified: 40 of 2922018, Human clinical research: 101 of 3012018, Preclinical (animal, in vitro, computational): 106 of 3012018, Reviews and meta-analyses: 80 of 3012018, Other and not yet classified: 14 of 3012019, Human clinical research: 114 of 3262019, Preclinical (animal, in vitro, computational): 129 of 3262019, Reviews and meta-analyses: 48 of 3262019, Other and not yet classified: 35 of 3262020, Human clinical research: 112 of 3062020, Preclinical (animal, in vitro, computational): 122 of 3062020, Reviews and meta-analyses: 52 of 3062020, Other and not yet classified: 20 of 3062021, Human clinical research: 117 of 3182021, Preclinical (animal, in vitro, computational): 114 of 3182021, Reviews and meta-analyses: 73 of 3182021, Other and not yet classified: 14 of 3182022, Human clinical research: 113 of 2852022, Preclinical (animal, in vitro, computational): 98 of 2852022, Reviews and meta-analyses: 55 of 2852022, Other and not yet classified: 19 of 2852023, Human clinical research: 124 of 3072023, Preclinical (animal, in vitro, computational): 102 of 3072023, Reviews and meta-analyses: 68 of 3072023, Other and not yet classified: 13 of 3072024, Human clinical research: 168 of 4122024, Preclinical (animal, in vitro, computational): 119 of 4122024, Reviews and meta-analyses: 107 of 4122024, Other and not yet classified: 18 of 4122025, Human clinical research: 162 of 4832025, Preclinical (animal, in vitro, computational): 140 of 4832025, Reviews and meta-analyses: 155 of 4832025, Other and not yet classified: 26 of 4832026 (to date), Human clinical research: 170 of 4772026 (to date), Preclinical (animal, in vitro, computational): 118 of 4772026 (to date), Reviews and meta-analyses: 172 of 4772026 (to date), Other and not yet classified: 17 of 477Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified020040060020012007201320192026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
200102002
200232005
200322105
200430508
200511619
200621339
20072417124
20087314125
2009121029758
2010176521792
20113518579119
201239305113133
201354363812140
201480644111196
2015101755529260
2016100657640281
2017104767240292
20181011068014301
20191141294835326
20201121225220306
20211171147314318
2022113985519285
20231241026813307
202416811910718412
202516214015526483
2026 (to date)17011817217477

Study types

Animal study1,131
Review921
Observational human study731
Randomized controlled trial648
Editorial, letter or other328
Meta-analysis234
In vitro study212
Case report185
Other clinical trial179
Systematic review172
Computational study100
Not yet classified20
Guideline or consensus12

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health3,742
Endocrinology2,534
Obesity and weight management1,429
Cardiovascular819
Neurological and mental health535
Gastrointestinal474
Immune system290
Reproductive and sexual health244
Cognitive health152
Oncology141
Musculoskeletal130
Tissue repair84

Registered clinical trials

101 of 339 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 343 · Unknown status: 54 · Terminated: 20 · Withdrawn: 14 · Recruiting: 13 · Active, not recruiting: 9 · Not yet recruiting: 2 · Enrolling by invitation: 1 · Suspended: 1
Early phase 1: 5 · Phase not applicable: 88 · Phase 1: 64 · Phase 1 / Phase 2: 6 · Phase 2: 60 · Phase 2 / Phase 3: 6 · Phase 3: 106 · Phase 4: 122

TrialStatusPhaseStartedResults
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437 · 120 enrolledNot yet recruitingPhase 42026-05—
The Evira Study: Additional Support During Obesity TreatmentNCT06836284 · 40 enrolledRecruitingPhase not applicable2026-02—
Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesNCT07640139 · 125,000 enrolledEnrolling by invitationPhase not applicable2026-01—
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816 · 71 enrolledRecruitingPhase 12025-11—
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 DiabetesNCT06976619 · 60 enrolledRecruitingPhase 22025-10—
A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and OsteoarthritisNCT07225829 · 130 enrolledCompletedPhase 22025-06—
Liraglutide Treatment in Obese Infertile PCOS WomenNCT06742710 · 890 enrolledRecruitingPhase 42025-05—
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)NCT07029009 · 50 enrolledRecruitingPhase 22025-05—
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures AloneNCT06865365 · 72 enrolledNot yet recruitingPhase 42025-05—
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic ControlNCT07244003 · 430 enrolledRecruitingPhase 42025-03—
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsNCT07325435 · 60 enrolledActive, not recruitingPhase 42024-12—
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac SurgeryNCT06361238 · 260 enrolledRecruitingPhase 32024-11—
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 AgonistsNCT06818292 · 10 enrolledCompletedPhase not applicable2024-10—
Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908 · 183 enrolledCompletedPhase 32024-08—
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 DiabetesNCT06559722 · 510 enrolledUnknown statusPhase 32024-08—
Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyNCT06533527 · 69 enrolledCompletedPhase 42024-07Posted
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2DNCT06439056 · 12 enrolledCompletedPhase 12024-05—
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese SubjectsNCT06449703 · 44 enrolledUnknown statusPhase 12024-05—
LIROH - Liraglutide for Obesity in HIVNCT06438146 · 40 enrolledUnknown statusPhase 42024-05—
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.NCT06283641 · 300 enrolledCompletedPhase not applicable2024-04—
Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219 · 30 enrolledActive, not recruitingPhase 42024-03—
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory IssuesNCT06171152 · 30 enrolledSuspendedEarly phase 12024-01—
Pharmacological Treatment - An Overview of Its Role in Managing Childhood ObesityNCT07304141 · 128 enrolledCompletedPhase not applicable2023-12—
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and InfertilityNCT05952882 · 188 enrolledUnknown statusPhase 32023-11—
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver DiseaseNCT06501326 · 102 enrolledUnknown statusPhase 42023-11—
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKDNCT07309094 · 250 enrolledRecruitingPhase not applicable2023-09—
Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic SurgeryNCT07374445 · 100 enrolledCompletedPhase 42023-09—
Anti-obesity Pharmacotherapy and InflammationNCT05756764 · 30 enrolledActive, not recruitingPhase not applicable2023-06—
Effects of GH and Lirglutide on AgRPNCT05681299 · 40 enrolledRecruitingPhase 42023-05—
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes MellitusNCT05268237 · 15 enrolledRecruitingPhase 1, Phase 22023-04—
The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without DiabetesNCT07913685 · 83 enrolledCompletedPhase 42023-04—
Obesity Treatment to Improve DiabetesNCT05390307 · 60 enrolledCompletedPhase not applicable2023-04—
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesNCT05794581 · 32 enrolledCompletedPhase 12023-03—
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes MellitusNCT05779644 · 300 enrolledUnknown statusPhase not applicable2023-02—
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in AmericaNCT05579249 · 500 enrolledCompletedPhase 42023-01Posted
POSE2.0 With GLP-1 Agonist for Obesity ManagementNCT05705388 · 50 enrolledUnknown statusPhase not applicable2023-01—
Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic SurgeryNCT06201819 · 37 enrolledCompletedPhase 42022-12—
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 AnalogueNCT05767255 · 66 enrolledUnknown statusPhase 32022-12—
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot StudyNCT06217848 · 50 enrolledUnknown statusEarly phase 12022-11—
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in NondiabeticsNCT04466566 · 21 enrolledCompletedPhase 32022-10Posted
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · 396 enrolledCompletedPhase not applicable2022-10—
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical RecordsNCT05438186WithdrawnPhase not applicable2022-09—
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic KneeNCT05419856 · 34 enrolledCompletedPhase 12022-08Posted
A Study of LY3537021 in Healthy ParticipantsNCT05444569 · 47 enrolledCompletedPhase 12022-08—
Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes MellitusNCT05467514 · 35 enrolledCompletedPhase 32022-07—
Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )NCT05221229 · 29 enrolledActive, not recruitingPhase not applicable2022-04—
Efficacy of Liraglutide Therapy in Patients With IPAANCT04763564 · 8 enrolledTerminatedPhase 22022-03Posted
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.NCT05285397 · 60 enrolledUnknown statusPhase not applicable2022-03—
Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight LossNCT05268627 · 38 enrolledUnknown statusPhase not applicable2022-01—
A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in SwitzerlandNCT05153590 · 269 enrolledCompletedPhase not applicable2021-12—

The 50 most recently started of 457 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis.

    European journal of clinical pharmacology · October 24, 2026 · Meta-analysis · cited 0 times

    PMID 42920001 · DOI 10.1007/s00228-026-04206-4 · Reviews and meta-analyses

  2. GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials.

    Sleep & breathing = Schlaf & Atmung · October 6, 2026 · Meta-analysis · cited 0 times

    PMID 42837024 · DOI 10.1007/s11325-026-03826-5 · Reviews and meta-analyses

  3. Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.

    Diabetes, obesity & metabolism · September 21, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42768849 · DOI 10.1111/dom.71358 · Reviews and meta-analyses

  4. Glucagon-like receptor-1 agonists and impotence: A meta-analysis.

    World journal of methodology · September 20, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42626264 · DOI 10.5662/wjm.119385 · Reviews and meta-analyses

  5. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.

    Drugs · September 12, 2026 · Meta-analysis · cited 1 times · open access

    PMID 42730869 · DOI 10.1007/s40265-026-02365-3 · Reviews and meta-analyses

  6. Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.

    PeerJ · September 8, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42729958 · DOI 10.7717/peerj.21713 · Reviews and meta-analyses

  7. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.

    Frontiers in endocrinology · August 26, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42718598 · DOI 10.3389/fendo.2026.1870008 · Reviews and meta-analyses

  8. Safety and Efficacy of Glucagon Like Peptide-1 Receptor Agonism-Based Therapies in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · August 4, 2026 · Meta-analysis · cited 0 times

    PMID 42551699 · DOI 10.1016/j.eprac.2026.07.018 · Reviews and meta-analyses

  9. Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.

    Endocrine · July 31, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42536323 · DOI 10.1007/s12020-026-04701-9 · Reviews and meta-analyses

  10. Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.

    Schizophrenia research · July 24, 2026 · Meta-analysis · cited 1 times

    PMID 42497473 · DOI 10.1016/j.schres.2026.06.025 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

    The New England journal of medicine · June 13, 2016 · Randomized controlled trial · cited 7,608 times · open access

    PMID 27295427 · DOI 10.1056/nejmoa1603827 · Human clinical research

  2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

    Lancet (London, England) · November 1, 2006 · Review · cited 3,901 times

    PMID 17098089 · DOI 10.1016/s0140-6736(06)69705-5 · Reviews and meta-analyses

  3. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

    The New England journal of medicine · July 1, 2015 · Randomized controlled trial · cited 2,712 times · open access

    PMID 26132939 · DOI 10.1056/nejmoa1411892 · Human clinical research

  4. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

    Lancet (London, England) · November 20, 2015 · Randomized controlled trial · cited 2,196 times · open access

    PMID 26608256 · DOI 10.1016/s0140-6736(15)00803-x · Human clinical research

  5. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

    The lancet. Diabetes & endocrinology · August 14, 2019 · Meta-analysis · cited 1,658 times · open access

    PMID 31422062 · DOI 10.1016/s2213-8587(19)30249-9 · Reviews and meta-analyses

Latest publications

  1. Hyperglycemia promotes maladaptive Dectin-1 signaling and impairs skin antifungal host defense.

    Infection and immunity · November 12, 2026 · Animal study · cited 3 times · open access

    PMID 43018239 · DOI 10.1128/iai.00326-26 · Animal studies

  2. Excessive Intrapancreatic Fat Deposition and the Potential Therapeutic Role of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · November 10, 2026 · Systematic review · cited 0 times

    PMID 43008789 · DOI 10.1055/a-2988-3090 · Reviews and meta-analyses

  3. Effectiveness of GLP-1 RAs and SGLT-2is for Weight Loss and Glycaemic Control: An Observational Emulation of a Target Trial.

    Diabetes, obesity & metabolism · November 9, 2026 · Observational human study · cited 0 times · open access

    PMID 43003406 · DOI 10.1111/dom.71515 · Human clinical research

  4. Psychiatric symptoms, psychological well-being and quality of life after metabolic and bariatric surgery versus incretin-based therapy in obesity: The role of weight loss.

    General hospital psychiatry · November 4, 2026 · Observational human study · cited 0 times · open access

    PMID 42994195 · DOI 10.1016/j.genhosppsych.2026.10.008 · Human clinical research

  5. GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study.

    Balkan medical journal · November 2, 2026 · Observational human study · cited 0 times · open access

    PMID 42969666 · DOI 10.4274/balkanmedj.galenos.2026.2026-7-49 · Human clinical research

  6. The effect of glucagon-like peptide-1 receptor agonists on bone metabolism: A systematic review and meta-analysis of randomized placebo-controlled trials of predominantly first-generation agents.

    Bone · November 2, 2026 · Review · cited 0 times

    PMID 42971377 · DOI 10.1016/j.bone.2026.118160 · Reviews and meta-analyses

  7. Liraglutide and Semaglutide Induce Nitric Oxide-Dependent Contraction of Larger and Relaxation of Smaller Porcine Retinal Resistance Vessels Ex Vivo.

    Investigative ophthalmology & visual science · November 1, 2026 · Animal study · cited 0 times · open access

    PMID 42975103 · DOI 10.1167/iovs.67.13.7 · Animal studies

  8. Liraglutide Dose Affordability and Durability in Real-World Obesity Care.

    Endocrinology, diabetes & metabolism · November 1, 2026 · Editorial, letter or other · cited 0 times · open access

    PMID 42867112 · DOI 10.1002/edm2.70364 · Commentary and other

  9. Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists: A systematic review.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · November 1, 2026 · Systematic review · cited 0 times · open access

    PMID 42033237 · DOI 10.1093/ajhp/zxag121 · Reviews and meta-analyses

  10. Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment.

    Diabetic medicine : a journal of the British Diabetic Association · October 31, 2026 · Not yet classified · cited 0 times

    PMID 42965922 · DOI 10.1111/dme.70524 · Not yet classified

Browse all 4,873 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Liraglutida; Liraglutide; Liraglutidum; NN2211; Saxenda; Victoza

((TITLE_ABS:"Liraglutida" OR CHEM:"Liraglutida") OR (TITLE_ABS:"Liraglutide" OR CHEM:"Liraglutide") OR (TITLE_ABS:"Liraglutidum" OR CHEM:"Liraglutidum") OR (TITLE_ABS:"NN2211" OR CHEM:"NN2211" OR TITLE_ABS:"NN 2211" OR CHEM:"NN 2211") OR (TITLE_ABS:"Saxenda" OR CHEM:"Saxenda") OR (TITLE_ABS:"Victoza" OR CHEM:"Victoza")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Liraglutide research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/liraglutide